Department of Breast Cancer and Reconstructive Surgery, The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Cancer. 2010 Sep 15;116(18):4238-47. doi: 10.1002/cncr.25391.
The aim of this study was to assess the role of systemic treatment after whole-brain radiotherapy (WBRT) in immunohistochemically defined biological subsets of breast cancer patients with brain metastases.
The group of 420 consecutive breast cancer patients with brain metastases treated at the same institution between the years of 2003 to 2009 was analyzed. Patients were divided into 4 immunohistochemically biological subsets, based on the levels of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) receptors, and labeled as luminal A, luminal B, HER2, and triple-negative. Survival from brain metastases with and without systemic treatment after WBRT was calculated in 4 subsets.
In the entire group, the median survival from brain metastases in patients without and with systemic treatment after WBRT was 3 and 10 months, respectively (P < .0001). In the triple-negative subset, the median survival from brain metastases with and without systemic treatment was 4 and 3 months (P = .16), and in the luminal A subset, it was 12 and 3 months, respectively (P = .003). In the luminal B subset, the median survival without further treatment, after chemotherapy and/or hormonal therapy, and after chemotherapy and/or hormonal therapy with targeted therapy was 2 months, 9 months, and 15 months, respectively (P < .0001). In the HER2 subset, the median survival was 4 months, 6 months, and 13 months, respectively (P < .0001). No significant response to systemic treatment was noted in the triple-negative breast cancer population.
Systemic therapy, ordered after WBRT, appears to improve survival in patients with the luminal A, luminal B, and HER2 breast cancer subtypes. Targeted therapy was found to have an additional positive impact on survival. In patients with triple-negative breast cancer, the role of systemic treatment after WBRT appears to be less clear, and therefore this issue requires further investigation.
本研究旨在评估全身治疗在免疫组织化学定义的乳腺癌脑转移患者的生物学亚组中的作用。
分析了 2003 年至 2009 年期间在同一机构接受治疗的 420 例连续乳腺癌脑转移患者。根据雌激素、孕激素和人表皮生长因子受体 2(HER2)受体的水平,将患者分为 4 个免疫组织化学生物学亚组,并分别标记为 luminal A、luminal B、HER2 和三阴性。计算了全身治疗与 WBRT 后全身治疗的 4 个亚组的脑转移生存情况。
在整个组中,无全身治疗和有全身治疗的患者的脑转移中位生存时间分别为 3 个月和 10 个月(P <.0001)。在三阴性亚组中,有全身治疗和无全身治疗的脑转移中位生存时间分别为 4 个月和 3 个月(P =.16),在 luminal A 亚组中分别为 12 个月和 3 个月(P =.003)。在 luminal B 亚组中,无进一步治疗、化疗和/或激素治疗后、化疗和/或激素治疗联合靶向治疗后的中位生存时间分别为 2 个月、9 个月和 15 个月(P <.0001)。在 HER2 亚组中,中位生存时间分别为 4 个月、6 个月和 13 个月(P <.0001)。在三阴性乳腺癌患者中,全身治疗未见明显反应。
WBRT 后序贯全身治疗似乎可改善 luminal A、luminal B 和 HER2 乳腺癌亚型患者的生存。靶向治疗对生存有额外的积极影响。在三阴性乳腺癌患者中,WBRT 后全身治疗的作用似乎不太明确,因此需要进一步研究。